Interrupted vs. continued maintenance therapy in childhood acute leukemia

Area of Science:

• Pediatric Oncology
• Hematology
• Clinical Pharmacology

Background:

• Childhood acute leukemia remains a significant health challenge.
• Effective remission induction and maintenance are crucial for patient outcomes.

Purpose of the Study:

• To evaluate the impact of continuing vs. discontinuing oral maintenance therapy on remission duration in childhood acute leukemia.
• To compare the efficacy of 6-mercaptopurine, methotrexate, and cyclophosphamide as maintenance agents.

Main Methods:

• A total of 313 patients with childhood acute leukemia were initially treated with vincristine and prednisone.
• Patients achieving complete bone marrow remission were randomized to maintenance with 6-mercaptopurine, methotrexate, or cyclophosphamide.
• Further randomization occurred at 2 and 6 months to either continue or discontinue maintenance therapy.

Main Results:

• Continuing maintenance therapy at both 2 and 6 months demonstrated significantly longer remission durations across all agents compared to discontinuation.
• For patients randomized at 2 months, median remission lengths were 37 vs. 19 weeks (6-MP), 25 vs. 14 weeks (MTX), and 29 vs. 13 weeks (CYC).
• For patients randomized at 6 months, median remission lengths were 57 vs. 17 weeks (6-MP), 60 vs. 40 weeks (MTX), and 23 vs. 10 weeks (CYC).

Conclusions:

• Continuing maintenance therapy is advantageous for prolonging bone marrow remission in childhood acute leukemia.
• The benefit of continuing therapy was observed at both early (2 months) and later (6 months) time points.
• This study supports the importance of sustained maintenance regimens in pediatric leukemia treatment protocols.